Keyphrases
Bendamustine
9%
Chemoimmunotherapy
9%
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Complete Response Rate
9%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
9%
Lactate Dehydrogenase
9%
Lymphoma
9%
Lymphoma Patients
9%
Matched Cohort Analysis
100%
Median Overall Survival
9%
Median Progression-free Survival
9%
Overall Response Rate
9%
Overall Survival
18%
Patient Characteristics
9%
Polatuzumab
100%
Progression-free Survival
18%
Propensity Score Matching
9%
Refractory Diffuse Large B-cell Lymphoma
27%
Relapsed or Refractory
100%
Response Rate
9%
Rituximab
9%
Treatment Line
9%
Treatment-related Mortality
9%
Medicine and Dentistry
Arm
12%
Bendamustine
12%
Chemoimmunotherapy
12%
Chimeric Antigen Receptor
100%
Chimeric Antigen Receptor T-Cell
100%
Cohort Analysis
100%
Diffuse Large B-Cell Lymphoma
37%
Lactate Dehydrogenase
12%
Oncology
12%
Overall Survival
37%
Patient Characteristics
12%
Progression Free Survival
37%
Propensity Score Matching
12%
Rituximab
12%
Pharmacology, Toxicology and Pharmaceutical Science
Bendamustine
10%
Chimeric Antigen Receptor
100%
Diffuse Large B Cell Lymphoma
30%
Lactate Dehydrogenase
10%
Overall Survival
30%
Progression Free Survival
30%
Rituximab
10%